207 related articles for article (PubMed ID: 27629559)
1. Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.
Keehn A; Ludmir E; Taylor J; Rabbani F
World J Urol; 2017 May; 35(5):713-720. PubMed ID: 27629559
[TBL] [Abstract][Full Text] [Related]
2. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
[TBL] [Abstract][Full Text] [Related]
3. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
4. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
6. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
Abdel-Wahab M; Reis IM; Hamilton K
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
[TBL] [Abstract][Full Text] [Related]
7. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
[TBL] [Abstract][Full Text] [Related]
8. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
9. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis.
Singh AK; Mashtare TL; McCloskey SA; Seixas-Mikelus SA; Kim HL; May KS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1086-94. PubMed ID: 20350797
[TBL] [Abstract][Full Text] [Related]
10. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
[TBL] [Abstract][Full Text] [Related]
11. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in the risk of second primary bladder cancer following radiation therapy among localized prostate cancer patients.
Zhang L; Hsieh MC; Allison C; Devane M; Hicks C; Yu Q; Shi L; Wu J; Wu XC
Cancer Epidemiol; 2021 Aug; 73():101967. PubMed ID: 34146916
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer.
Chrouser K; Leibovich B; Bergstralh E; Zincke H; Blute M
J Urol; 2005 Jul; 174(1):107-10; discussion 110-1. PubMed ID: 15947588
[TBL] [Abstract][Full Text] [Related]
14. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
15. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.
Jarosek SL; Virnig BA; Chu H; Elliott SP
Eur Urol; 2015 Feb; 67(2):273-80. PubMed ID: 25217421
[TBL] [Abstract][Full Text] [Related]
16. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
[TBL] [Abstract][Full Text] [Related]
17. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
[TBL] [Abstract][Full Text] [Related]
18. Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.
Ashamalla H; Guirguis A; McCool K; McVorran S; Mattes M; Metzger D; Oromendia C; Ballman KV; Mokhtar B; Tchelebi M; Katsoulakis E; Rafla S
Brachytherapy; 2017; 16(2):323-329. PubMed ID: 28139417
[TBL] [Abstract][Full Text] [Related]
19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
20. Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
Wu GX; Nelson RA; Kim JY; Raz DJ
Clin Lung Cancer; 2017 Sep; 18(5):543-550.e3. PubMed ID: 28412093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
